Outlook Therapeutics
@OutlookTx
$OTLK is a late clinical stage biopharma company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications.
01-06-2020 19:25:49
305 Tweets
650 Followers
123 Following
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million.
bit.ly/3xz9iwh
#wetAMD #ophthalmology #retinadisease